Analyst Ananda Ghosh of H.C. Wainwright reiterated a Buy rating on Inventiva, boosting the price target to $24.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight the potential of Inventiva’s lead drug, Lanifibranor, in the treatment of MASH. Lanifibranor is distinguished as the only oral therapy targeting fibrosis with systemic metabolic benefits, setting it apart in a field where existing treatments have limited efficacy. If the ongoing NATIV3 trial confirms previous positive results, Lanifibranor could become a foundational oral therapy for MASH, akin to the role of ACE inhibitors in hypertension.
Additionally, recent acquisitions in the sector underscore the strategic value of differentiated MASH assets, suggesting that Lanifibranor’s unique profile could make it an attractive acquisition target. The drug’s ability to improve insulin sensitivity and glycemic control, along with its favorable impact on weight and cardiovascular health, further supports its potential as a leading therapy. Consequently, Ghosh has increased the price target for Inventiva, reflecting the promising outlook for Lanifibranor in the evolving MASH therapeutic landscape.
In another report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $20.00 price target.